A systematic review of the adverse effects of tacrolimus in organ transplant patients

African Journal of Pharmacy and Pharmacology

Volumn 5, Issue 6, 2011, Pages 764-771

  Teh, L K ^a   Dom, S H M ^a   Zakaria, Z A ^b   Salleh, M Z ^a  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^b UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Diabetes mellitus; Efficacy; Hypertension; Neurotoxicity; Tacrolimus

Indexed keywords

TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ADVERSE OUTCOME; BIOPSY TECHNIQUE; CLINICAL EVALUATION; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG EFFICACY; END STAGE LIVER DISEASE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; META ANALYSIS; NEUROTOXICITY; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; REVIEW; SCORING SYSTEM; SURVIVAL TIME; SYSTEMATIC REVIEW;

EID: 79960216584     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: 10.5897/AJPP10.104     Document Type: Review

References (16)

1. Bottiger Y, Brattstrom C, Tyden G, Sawe J, Groth CG (1999). Tacrolimus whole blood concentrations correlate closely to sideeffects in renal transplant recipients. Br. J. Clin. Pharm., 48: 445-448.
2. Demirbas A, Tuncer M, Yavuz A, Gurkan A, Kacar S, Cetinkaya R, Tekin S, Akbas SH, Akaydin M, Ersoy F, Yakupoglu G (2003). Influence of Tacrolimus plus Mycophenolate Mofetil Regimens on Acute Rejection Rate and Diabetes Mellitus Development in Renal Transplant Recipients. Transplant Proc., 36: 175-177.
3. Jurewicz WA (2003). Tacrolimus versus cyclosporin immunosuppression: long-term outcome in renal transplantation. Nephrol. Dial. Transplant, 18: I7-I11.
4. Kelly PA, Burckart GJ, Venkataramanan R (1995). Tacrolimus: a new immunosuppressive agent. Am. J. Health Syst. Pharm., 52: 1521-1535.
5. Knoll GA, Bell RC (1999). Tacrolimus versus Cyclosporin for Immunosuppression in Renal Transplantation: Meta-Analysis of Randomized Trials. Br. Med. J., 3: 1104-1107.
6. Margarit C, Bilbao I, Castells L, Lopez I, Pou L, Allende E, Escartin A (2005). A Prospective Randomized Trial Comparing Tacrolimus and Steroids with Tacrolimus Monotherapy in Liver Transplantation: The Impact on Recurrence of Hepatitis C. Transplant Int., 18: 1336-1345.
7. Margreiter R, European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group (2002). Efficacy & Safety of Tacrolimus Compared with Microemulsified-Cyclosporine in Renal Transplantation: A Randomized Multicentre Study. Lancet, 359: 741-745.
8. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, Eigler FW, Heemann U, Pichlmayr R, Behrend M, Vanrenterghem Y, Donck J, van Hooff J, Christiaans M, Morales JM, Andres A, Johnson RWG, Short C, Buchholz B, Rehmer N, Land W, Schleibner S, Fosythe JLR, Talbot D, Neumayer HH, Hauser I, Ericzon BG, Brattstrom C, Claesson K, Muhlbacher F, Pohanka E (1997). Multicentre Randomized Trial Comparing Tacrolimus (FK506) & Cyclosporine in the Prevention of Renal Allograft Rejection: A Report of European TAC Multicenter Renal Study Group. Transplantation, 64: 436-443.
9. McAlister VC, Haddad E, Renoul E, Malthaner RA, Kjaer MS, Gluud LL (2006). Cyclosporin versus Tacrolimus as Primary Immunosuppressant After Liver Transplantation: A Meta-Analysis. Am. J. Transplant, 6: 1578-1585.
10. Moench C, Barreiros AP, Schuchmann M, Bittinger F, Thiesen J, Hommel G, Kraemer I, Otto G (2007). Tacrolimus Monotherapy without Steroids after Liver Transplantation: A Prospective Randomized Double-Blinded Placebo Controlled Trial. Am. J. Transplant, 7: 1616-1623
11. Murphy GJ, Waller JR, Sandford RS, Furness PN, Nicholson ML (2003). Randomized Clinical Trial of Effect of Microemulsion Cyclosporin and Tacrolimus on Renal Allograft Fibrosis. Br. J. Surg., 90: 680-686.
12. O'grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A, UK and Republic of Ireland Liver Transplant Study Group (2002). Tacrolimus versus Microemulsified Ciclosporin in Liver Transplantation: The TMC Randomised Controlled Trial. Lancet, 360: 1119-1125.
13. Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP (1996). Effects of Tacrolimus (FK506) on Human Insulin Gene Expression, Insulin mRNA Levels and Insulin Secretion in HIT-T15 Cells. J. Clin. Invest., 98: 2786-2793.
14. Tan TC, Robinson PJ (2006). Mechanisms of Calcineurin Inhibitor-Induced Neurotoxicity. Transplant. Rev., 20: 49-60.
15. The US Multicenter FK 506 Liver Study Group (1994). A Comparison of Tacrolimus (FK506) & Cyclosporine for Immunosuppression in Liver Transplantation. N. Eng. J. Med., 331: 1110-1115.
16. Wingard JR, Nash RA, Przepiorka D, Klein JL, Weisdorf DJ, Fay JW, Zhu J, Maher RM, Fitzsimmons WE, Ratanatharathorn V (1998). Relationship of Tacrolimus (FK506) Whole Blood Concentrations and Efficacy and Safety after HLA-Identical Sibling Bone Marrow Transplantation. Biol. Blood Marrow Transplant., 4: 157-163